MR Imaging Characterization of Microvessels in Experimental Breast Tumors by Using a Particulate Contrast Agent with Histopathologic Correlation

Turetschek, Karl; Huber, Sabine; Floyd, Eugenia; Helbich, Thomas H.; Roberts, Timothy P. L.; Shames, David M.; Tarlo, Kirk; Wendland, Michael F.; Brasch, Robert C.

doi:10.1148/radiology.218.2.r01fe37562

Cited by 131 publications

(99 citation statements)

References 44 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By comparison, the blood pool agent albumin(Gd-DTPA) 30 is largely retained in the intravascular space with a half-life of 88min after intravenous injection and can remain in the bloodtstream and extravascular compartment two weeks after injection. (77,78) These undesirably long retention times have precluded its use in the clinic.…”

Section: Resultsmentioning

confidence: 99%

Development of Contrast Agents Targeted to Macrophage Scavenger Receptors for MRI of Vascular Inflammation

2006

View full text Add to dashboard Cite

Atherosclerosis is a leading cause of death in the U.S. Because there is a potential to prevent coronary and arterial diseases through early diagnosis, there is a need for methods to image arteries in the subclinical stage as well as clinical stage using various non-invasive techniques, including Magnetic Resonance Imaging (MRI). We describe a development of a novel MRI contrast agent targeted to plaques that will allow imaging of lesion formation. The contrast agent is directed to macrophages, one of the earliest components of developing plaques. Macrophages are labeled through the macrophage scavenger receptor A, a macrophage specific cell surface protein, using an MRI contrast agent derived from scavenger receptor ligands. We have synthesized and characterized these contrast agents with a range of relaxivities. In vitro studies show that the targeted contrast agent accumulates in macrophages and solution studies indicate that micromolar concentrations are sufficient to produce contrast in an MR image. Cell toxicity and initial biodistribution studies indicate low toxicity, no detectable retention in normal blood vessels, and rapid clearance from blood. The promising performance of this contrast agent targeted towards vascular inflammation opens doors to tracking of other inflammatory diseases such as tumor immunotherapy and transplant acceptance using MRI.

show abstract

Section: Resultsmentioning

confidence: 99%

Development of Contrast Agents Targeted to Macrophage Scavenger Receptors for MRI of Vascular Inflammation

2006

View full text Add to dashboard Cite

show abstract

“…68 In addition, superparamagnetic contrast agents such as iron oxide particles (ultrasmall superparamagnetic iron oxide) successfully determined blood volume and tumor vasculature on the basis of the phagocytic activity of macrophages. 69 Nevertheless, the evaluation of plaque neovessels with the use of MRI-ultrasmall superparamagnetic iron oxide has not been published yet.…”

Section: Neovascularization and Imagingmentioning

confidence: 99%

Neovascularization in Human Atherosclerosis

Moreno¹,

Purushothaman²,

Zias³

et al. 2006

CMM

247

229

View full text Add to dashboard Cite

“…Reflux k is commonly set to zero in DCE-MRI studies that use large-molecular contrast agents [7,16]. In our study, k was calculated, but no conclusions were drawn that pertained to differences between treatment groups or differences within a tumour.…”

Section: Discussionmentioning

confidence: 95%

“…This region of interest was used for further analysis. Regions of interest for the tumour rim were defined as the approximately 1 to 2 mm-thick peripheral zone of strong contrast enhancement [7] in the dynamic T 1 -weighted series; the tumour core was the remaining central region.…”

Section: Analysis Of Mri Datamentioning

confidence: 99%

“…New techniques for monitoring the effects of anti-angiogenesis treatment that are less or non-invasive are currently under investigation [6]. Dynamic contrast-enhanced, T 1 -weighted magnetic resonance imaging (DCE-MRI) [6][7][8][9] is a noninvasive imaging technique that can be used to derive microcirculation properties that mark tumour angiogenesis [7,10]. Various models have been investigated that relate changes in signal intensity over time as measured with DCE-MRI to tumour activity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice

Lussanet¹,

Beets-Tan²,

Backes³

et al. 2004

European Journal of Cancer

View full text Add to dashboard Cite

The purpose of this study was to evaluate the effects of anginex on tumour angiogenesis assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine. C57BL/6 mice carrying B16F10 melanomas were treated with anginex, TNP-470 or saline. Tumour growth curves and microvessel density (MVD) were recorded to establish the effects of treatment. DCE-MRI was performed on day 16 after tumour inoculation, and the endothelial transfer coefficients of the microvessel permeability surface-area product (K PS ) were calculated using a two-compartment model. Both anginex and TNP-470 resulted in smaller tumour volumes (P< 0.0001) and lower MVD (P <0.05) compared to saline. Treatment with anginex resulted in a 64% reduction (P <0.01) of tumour K PS and TNP-470 resulted in a 44% reduction (P=0.17), compared to saline. DCE-MRI with a clinically available, small-molecular contrast agent can therefore be used to evaluate the angiostatic effects of anginex and TNP-470 on tumour angiogenesis. #

show abstract

MR Imaging Characterization of Microvessels in Experimental Breast Tumors by Using a Particulate Contrast Agent with Histopathologic Correlation

Cited by 131 publications

References 44 publications

Development of Contrast Agents Targeted to Macrophage Scavenger Receptors for MRI of Vascular Inflammation

Development of Contrast Agents Targeted to Macrophage Scavenger Receptors for MRI of Vascular Inflammation

Neovascularization in Human Atherosclerosis

Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice

Contact Info

Product

Resources

About